CY1114424T1 - Μεθοδος θεραπειας ή προφυλαξης - Google Patents

Μεθοδος θεραπειας ή προφυλαξης

Info

Publication number
CY1114424T1
CY1114424T1 CY20131100691T CY131100691T CY1114424T1 CY 1114424 T1 CY1114424 T1 CY 1114424T1 CY 20131100691 T CY20131100691 T CY 20131100691T CY 131100691 T CY131100691 T CY 131100691T CY 1114424 T1 CY1114424 T1 CY 1114424T1
Authority
CY
Cyprus
Prior art keywords
receptor
pneumonia
diabetic
treatment
present
Prior art date
Application number
CY20131100691T
Other languages
English (en)
Inventor
Maree Therese Smith
Bruce Douglas Wyse
Original Assignee
Spinifex Pharmaceuticals Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2004907332A external-priority patent/AU2004907332A0/en
Application filed by Spinifex Pharmaceuticals Pty Ltd filed Critical Spinifex Pharmaceuticals Pty Ltd
Publication of CY1114424T1 publication Critical patent/CY1114424T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)

Abstract

Η παρούσα εφεύρεση κατευθύνεται σε μεθόδους και μέσα που είναι χρήσιμα στην πρόληψη και την βελτίωση των σημείων και των συμπτωμάτων που συνδέονται με τον νευροπαθητικό πόνο. Ειδικότερα, η παρούσα εφεύρεση αποκαλύπτει την χρήση ανταγωνιστών υποδοχέα 2 (ΑΤ2 υποδοχέα) αγγειοτενσίνης II για την θεραπεία, προφύλαξη, αναστροφή και/ή συμπτωματική ανακούφιση από νευροπαθητικό πόνο, συμπεριλαμβανομένων μηχανικής υπεραλγησίας, θερμικής ή μηχανικής αλλοδυνίας, διαβητικού πόνου, και πόνου από παγίδευση νεύρου σε σπονδυλωτά ζώα και ειδικότερα σε ανθρώπινα υποκείμενα. Οι ανταγωνιστές ΑΤ2 υποδοχέων μπορεί να παρέχονται μόνοι τους ή σε συνδυασμό με άλλες ενώσεις, όπως εκείνες που είναι χρήσιμες στον έλεγχο των νευροπαθητικών καταστάσεων.
CY20131100691T 2004-12-24 2013-08-13 Μεθοδος θεραπειας ή προφυλαξης CY1114424T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2004907332A AU2004907332A0 (en) 2004-12-24 Method of Treatment or Prophylaxis
EP20050821524 EP1830869B1 (en) 2004-12-24 2005-12-23 Method of treatment or prophylaxis

Publications (1)

Publication Number Publication Date
CY1114424T1 true CY1114424T1 (el) 2016-10-05

Family

ID=36601295

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20131100691T CY1114424T1 (el) 2004-12-24 2013-08-13 Μεθοδος θεραπειας ή προφυλαξης

Country Status (17)

Country Link
US (5) US7795275B2 (el)
EP (3) EP2650011A1 (el)
JP (1) JP4966202B2 (el)
CN (3) CN101087619B (el)
CY (1) CY1114424T1 (el)
DK (1) DK1830869T3 (el)
ES (1) ES2425567T3 (el)
HK (1) HK1103364A1 (el)
HR (1) HRP20130738T1 (el)
ME (1) ME01597B (el)
NZ (1) NZ555334A (el)
PL (1) PL1830869T3 (el)
PT (1) PT1830869E (el)
RS (1) RS52927B (el)
SI (1) SI1830869T1 (el)
WO (1) WO2006066361A1 (el)
ZA (3) ZA200704909B (el)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7795275B2 (en) 2004-12-24 2010-09-14 Uniquest Pty Limited Method of treatment or prophylaxis
EP1996183A4 (en) * 2006-03-20 2010-04-14 Spinifex Pharm Pty Ltd METHOD FOR THE TREATMENT OR PROPHYLAXIS OF INFLAMMATORY PAIN
RU2009112397A (ru) * 2006-10-05 2010-10-10 Си Ви ТЕРАПЬЮТИКС, ИНК (US) Бициклические азотсодержащие гетероциклические соединения для применения в качестве ингибиторов стеароил соа десатуразы
US20090105283A1 (en) * 2007-04-11 2009-04-23 Dmitry Koltun 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
US20080255161A1 (en) * 2007-04-11 2008-10-16 Dmitry Koltun 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
US7828840B2 (en) * 2007-11-15 2010-11-09 Med Institute, Inc. Medical devices and methods for local delivery of angiotensin II type 2 receptor antagonists
WO2010045374A1 (en) * 2008-10-15 2010-04-22 Gilead Palo Alto, Inc. 3-hydroquinazolin-4-one derivatives for use as stearoyl coa desaturase inhibitors
WO2010056230A1 (en) * 2008-10-15 2010-05-20 Cv Therapeutics, Inc. 3-hydroquinazolin-4-one derivatives for use as stearoyl coa desaturase inhibitors
EP2525795B1 (en) * 2010-01-19 2015-10-21 Spinifex Pharmaceuticals Pty Ltd Methods and compositions for improved nerve conduction velocity
DE102010013075A1 (de) 2010-03-26 2011-09-29 B. Braun Melsungen Ag Antimikrobielle Wundauflage
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
US8614227B2 (en) 2010-07-21 2013-12-24 Spinifex Pharmaceuticals Pty Ltd Salt and solvates of a tetrahydroisoquinoline derivative
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
EP3392252B1 (en) 2011-08-23 2023-10-04 Libertas Bio, Inc. Pyrimido- pyridazinone compounds and use thereof
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
WO2013102242A1 (en) 2012-01-06 2013-07-11 Spinifex Pharmaceuticals Pty Ltd Heterocyclic compounds and methods for their use
AU2013202978B2 (en) 2012-01-25 2016-05-19 Novartis Ag Heterocyclic compounds and methods for their use
CN104470903B (zh) 2012-01-25 2017-02-22 诺华股份有限公司 杂环化合物和它们的使用方法
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
CN105358532B (zh) 2013-07-08 2019-07-23 诺华股份有限公司 杂环化合物和它们的使用方法
EP3051944B1 (en) 2013-09-30 2023-11-01 FMC Corporation Method of delivering an agriculturally active ingredient
WO2015109210A1 (en) 2014-01-17 2015-07-23 Cardioxyl Pharmaceuticals, Inc. N-hydroxymethanesulfonamide nitroxyl donors
WO2015144804A1 (en) 2014-03-26 2015-10-01 Astex Therapeutics Ltd Combinations
CA2943687C (en) 2014-03-26 2024-02-13 Astex Therapeutics Ltd Combinations of an fgfr inhibitor and an igf1r inhibitor
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
AR100936A1 (es) 2014-06-24 2016-11-09 Fmc Corp Formulaciones de espumas y concentrados emulsionables
WO2016113668A1 (en) 2015-01-13 2016-07-21 Novartis Ag Pyrrolidine derivatives as angiotensin ii type 2 antagonists
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
US10308628B2 (en) 2015-03-12 2019-06-04 Novartis Ag Heterocyclic compounds and methods for their use
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
CN106478502B (zh) * 2015-08-29 2021-04-27 上海翰森生物医药科技有限公司 1,2,3,4-四氢异喹啉衍生物、其制备方法和应用
CN108137546B (zh) 2015-09-23 2021-07-27 詹森药业有限公司 双杂芳基取代的1,4-苯并二氮杂卓化合物及其用于治疗癌症的用途
JP6898919B2 (ja) 2015-09-23 2021-07-07 ヤンセン ファーマシューティカ エヌ．ベー． 新規化合物
MX2018007634A (es) 2015-12-23 2018-09-21 Fmc Corp Tratamiento in situ de semilla en surco.
WO2018001997A1 (en) 2016-06-27 2018-01-04 Ratiopharm Gmbh Crystalline calcium salt of (s)-2-(diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinoline carboxylic acid
JP2019514862A (ja) 2017-03-23 2019-06-06 ノバルティス アーゲー （ｓ）−２−（ジフェニルアセチル）−１，２，３，４−テトラヒドロ−６−メトキシ−５−（フェニルメトキシ）−３−イソキノリンカルボン酸ナトリウムの無水結晶形
KR102132761B1 (ko) * 2017-06-09 2020-07-17 산동 단홍 파머수티컬 컴퍼니., 리미티드. At2r 수용체 길항제로서의 카르복시산 유도체
GB201710906D0 (en) * 2017-07-06 2017-08-23 Vicore Pharma Ab Compounds and methods for treating peripheral neuropathy
CN111902401B (zh) * 2018-02-23 2023-06-13 北京泰德制药股份有限公司 受体抑制剂、包含其的药物组合物及其用途
JP7438962B2 (ja) * 2018-03-23 2024-02-27 ベイジン タイド ファーマシューティカル カンパニー リミテッド 受容体阻害剤、同阻害剤を含む医薬組成物及びその使用
WO2019238962A1 (en) * 2018-06-14 2019-12-19 University College Cork - National University Of Ireland, Cork Peptide for disease treatment
WO2020012266A1 (en) 2018-07-12 2020-01-16 Novartis Ag Biocatalytic synthesis of olodanrigan (ema401) from 3-(2-(benzyloxy)-3-methoxyphenyl)propenoic acid with phenylalanine ammonia lyase
KR20240063881A (ko) 2021-07-30 2024-05-13 콘포 테라퓨틱스 엔.브이. 통증, 특히 신경병증성 통증, 및/또는 at2r 및/또는 at2r 매개 신호전달과 연관된 다른 질환 또는 장애의 치료를 위한 화합물
US20230373919A1 (en) 2022-05-17 2023-11-23 Eli Lilly And Company At2r antagonists and uses thereof

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3531485A (en) 1967-08-14 1970-09-29 American Home Prod Aryl-substituted diazabicycloalkanes
US3957795A (en) 1974-01-28 1976-05-18 Delmar Chemicals Limited Novel cyclopentene and cyclopentane derivatives
US3975795A (en) 1975-01-20 1976-08-24 Union Carbide Corporation Product stuffing apparatus and method
US4812462A (en) * 1986-04-01 1989-03-14 Warner-Lambert Company 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid analogs having antihypertensive activity
US5091390A (en) 1990-09-20 1992-02-25 E. I. Du Pont De Nemours And Company Treatment of CNS disorders with 4,5,6,7-tetrahydro-1H-imidazo (4,5-)-pyridines and analogs
JP3208139B2 (ja) 1990-10-02 2001-09-10 ワーナー−ランバート・コンパニー アンギオテンシン▲ｉｉ▼アンタゴニスト
US5385894A (en) 1991-03-06 1995-01-31 Merck & Co., Inc. Disubstituted 6-aminoquinazolinones
US5238942A (en) 1991-05-10 1993-08-24 Merck & Co., Inc. Substituted quinazolinones bearing acidic functional groups as angiotensin ii antagonists
WO1992020661A1 (en) * 1991-05-22 1992-11-26 Merck & Co., Inc. N, n-diacylpiperazines
US5204354A (en) 1992-02-14 1993-04-20 Merck & Co., Inc. Substituted quinazolinones as neurotensin antagonists useful in the treatment of CNS disorders
GB9208116D0 (en) 1992-04-13 1992-05-27 Ici Plc Therapeutic agents
EP0872235A1 (en) 1992-04-13 1998-10-21 Zeneca Limited Therapeutic agents
US5246943A (en) * 1992-05-19 1993-09-21 Warner-Lambert Company Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties
US5236934A (en) 1992-08-26 1993-08-17 E. I. Du Pont De Nemours And Company 1,2,3,4-tetrahydroisoquinolines useful in the treatment of CNS disorders
US5344830A (en) 1992-12-10 1994-09-06 Merck & Co., Inc. N,N-diacylpiperazine tachykinin antagonists
US5683997A (en) 1992-12-11 1997-11-04 Ciba-Geigy Corporation Substituted benzazepinones
US5395844A (en) 1993-06-10 1995-03-07 The Du Pont Merck Pharmaceutical Company Imidazole 5-position substituted angiotensin II antagonists
US5348955A (en) 1993-06-22 1994-09-20 Merck & Co., Inc. N,N-diacylpiperazines
US5338740A (en) 1993-07-13 1994-08-16 Pfizer Inc. Angiotensin II receptor antagonists
AP9400651A0 (en) 1993-07-15 1995-12-30 Pfizer Azacyclic-heterocyclic compounds as angiotensin II receptor antagonists.
US5409926A (en) 1993-07-19 1995-04-25 Merck & Co., Inc. AT-2 antagonist inhibition of vascular restenosis
US5610165A (en) 1994-02-17 1997-03-11 Merck & Co., Inc. N-acylpiperidine tachykinin antagonists
FR2739625B1 (fr) 1995-10-09 1997-12-05 Atochem Elf Sa Copolymeres hydrosolubles associatifs triblocs
GB2323783A (en) 1997-04-02 1998-10-07 Ferring Bv Group Holdings Inhibitors of farnesyl protein transferase
AU7696098A (en) 1997-08-11 1999-03-01 Algos Pharmaceutical Corporation Substance p inhibitors in combination with nmda-blockers for treating pain
US6277839B1 (en) 1998-10-07 2001-08-21 Merck Frosst Canada & Co. Biphenylene lactams as prostaglandin receptor ligands
TR200805741T2 (tr) * 1998-12-23 2008-10-21 Novartis Ag At-1 veya at-2 reseptörlerindeki artışın neden olduğu hastalıkların tedavisi için at-1 reseptör antagonisti veya at-2 reseptör modülatörünün kullanımı@
EP1237888B1 (en) * 1999-12-15 2006-09-13 Bristol-Myers Squibb Company Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
JP3901520B2 (ja) 1999-12-16 2007-04-04 ユニヴァースティ オブ サザーン カリフォルニア 粘膜組織の損傷の治療および予防法
AU6118001A (en) 2000-05-03 2001-11-12 Tularik Inc Combination therapeutic compositions and methods of use
JP2004503588A (ja) 2000-07-13 2004-02-05 ファルマシア・コーポレーション 全身性疼痛および頭痛に対する選択的シクロオキシゲナーゼ−２阻害薬および血管調節化合物
ATE303804T1 (de) 2000-11-17 2005-09-15 Warner Lambert Co Behandlung von sexueller funktionsstörung mit bombesin rezeptor antagonisten
EG23054A (en) 2001-01-22 2004-02-29 Sankyo Co Pyrrole derivatives their preparation and their therapeutic uses
WO2002060923A2 (en) 2001-01-29 2002-08-08 Cognetix, Inc. B-superfamily conotoxins
CA2436361C (en) 2001-01-29 2010-11-02 Takeda Chemical Industries, Ltd. Angiotensin ii antagonistic compound for use as analgesic and antiinflammatory agent
CA2470567A1 (en) 2001-12-14 2003-06-26 Targacept, Inc. Methods and compositions for treatment of central nervous system disorders
WO2003064414A1 (en) 2002-01-29 2003-08-07 Vicore Pharma Ab. Tricyclic compounds useful as angiotensin ii agonists
AR038377A1 (es) 2002-02-08 2005-01-12 Merck & Co Inc Derivados de n-bifenil-aminocicloalcancarboxamida (con sustitucion con metilo)
AU2003209851A1 (en) 2002-03-20 2003-09-29 The University Of Queensland Method of treatment and/or prophylaxis
JP2006500399A (ja) 2002-04-30 2006-01-05 メルク　エンド　カムパニー　インコーポレーテッド ナトリウムチャンネルブロッカーとしての、アリール−結合−アリール置換された、チアゾリジン−ジオンおよびオキサゾリジン−ジオン
AU2003236668A1 (en) 2002-05-17 2003-12-02 Faust Pharmaceuticals Methods for the prevention and/or the treatment of neurological disorders
AU2003237224A1 (en) 2002-05-29 2003-12-19 Merck And Co., Inc. 1,2 diamido cycloalkyl sodium channel blockers
GB0212412D0 (en) 2002-05-29 2002-07-10 Novartis Ag Combination of organic compounds
AU2003261167A1 (en) 2002-07-16 2004-02-02 Elan Pharma International, Ltd Liquid dosage compositions of stable nanoparticulate active agents
JO2397B1 (en) 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
DE10300973A1 (de) 2003-01-14 2004-07-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Carbonsäuren und deren Ester, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
PA8597401A1 (es) 2003-03-14 2005-05-24 Pfizer Derivados del acido 3-(1-[3-(1,3-benzotiazol-6-il) propilcarbamoil] cicloalquil) propanoico como inhibidores de nep
WO2004099248A2 (en) 2003-05-05 2004-11-18 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor agtr2 (agtr2)
US7157584B2 (en) 2004-02-25 2007-01-02 Takeda Pharmaceutical Company Limited Benzimidazole derivative and use thereof
US7795275B2 (en) * 2004-12-24 2010-09-14 Uniquest Pty Limited Method of treatment or prophylaxis
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin

Also Published As

Publication number Publication date
CN102049048A (zh) 2011-05-11
EP1830869A4 (en) 2010-08-11
CN102049048B (zh) 2013-12-25
EP1830869A1 (en) 2007-09-12
ZA201207323B (en) 2017-06-28
DK1830869T3 (da) 2013-08-26
EP2650010A1 (en) 2013-10-16
PL1830869T3 (pl) 2013-11-29
US9018207B2 (en) 2015-04-28
JP4966202B2 (ja) 2012-07-04
US8722675B2 (en) 2014-05-13
SI1830869T1 (sl) 2013-12-31
HRP20130738T1 (hr) 2013-10-25
ME01597B (me) 2014-09-20
US20140228362A1 (en) 2014-08-14
NZ555334A (en) 2010-05-28
US8492382B2 (en) 2013-07-23
JP2008531470A (ja) 2008-08-14
RS52927B (en) 2014-02-28
EP2650011A1 (en) 2013-10-16
ES2425567T3 (es) 2013-10-16
CN102861019B (zh) 2016-05-25
ZA201207322B (en) 2017-06-28
US8404686B2 (en) 2013-03-26
EP1830869B1 (en) 2013-05-22
US20060223741A1 (en) 2006-10-05
PT1830869E (pt) 2013-08-22
US20110318329A1 (en) 2011-12-29
CN101087619B (zh) 2012-12-05
CN101087619A (zh) 2007-12-12
US20120004259A1 (en) 2012-01-05
ZA200704909B (en) 2012-12-27
US20130296350A1 (en) 2013-11-07
US7795275B2 (en) 2010-09-14
WO2006066361A1 (en) 2006-06-29
HK1103364A1 (en) 2007-12-21
CN102861019A (zh) 2013-01-09

Similar Documents

Publication Publication Date Title
CY1114424T1 (el) Μεθοδος θεραπειας ή προφυλαξης
ATE423114T1 (de) Aminocyclopropancarbonsäureamidderivate als bradykininantagonisten
NI200600319A (es) Antagonistas de ccr2 de sal cuaternaria
CY1118887T1 (el) Φαρμακευτικες συνθεσεις ελεγχομενης αποδεσμευσης οι οποιες περιλαμβανουν εναν εστερα φουμαρικου οξεος
CY1116104T1 (el) Μεθοδος για την παρασκευη ρυθμιστων οπιοειδους
CY1105892T1 (el) Θepαπεια του ξανθωματος με παραγωγα αζετιδινονης ως αναστολεις απορροφησης στepολης
ATE409188T1 (de) Naphthyridinverbindungen
DE60314500D1 (de) Diaminopyrimidine und deren verwendung als angiogenesehemmer
ATE541590T1 (de) Modifizierte antikörper-fragmente
DE60312017D1 (de) Sulfonderivate zur hemmung von gamma-secretase
DE602004012858D1 (de) 2-aminobenzothiazole als cb1 rezeptor inverse agonisten
CY1115745T1 (el) Συνθεσεις και μεθοδοι για αντιμετωπιση ή προληψη σχετιζομενης με οξαλικα νοσου
ATE494904T1 (de) Verbindungen und verfahren zur erhöhung der neurogenese
DE60308996D1 (de) Melanocortinrezeptoragonisten
CY1106476T1 (el) Υποκατεστημενες διυδροκιναζολινες με αντι-ιικες ιδιοτητες
MA28935B1 (fr) Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite
NO20080010L (no) GPCR-agonister
TR201900542T4 (tr) Ağrı ve/veya enflamasyon tedavisi için bileşimler.
EA200600055A1 (ru) Агонисты рецептора меланокортина 4 (мк4 ) и их применение
ATE464287T1 (de) Cyclohexyl-sulphone als gamma-sekretase- inhibitoren
CR7432A (es) Amidas sustituidas activas del receptor de canabinoide-1
CY1111123T1 (el) Μεθοδοι χρησης υποδοχεα gpr119 για να πιστοποιουνται ενωσεις χρησιμες για αυξηση οστικης μαζας σε ενα ατομο
AR063494A1 (es) Anticuerpos agonistas anti notch3 y su uso en el tratamiento de las enfermedades relacionadas con el gen notch3
NO20051503L (no) Pyrazolopyridiner og fremgangsmater for fremstilling og anvendelse av de samme.
NO20054848L (no) Substituerte p-diaminobenzenderivater